Detalles de la búsqueda
1.
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
Lancet
; 402(10416): 1979-1990, 2023 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898137
2.
Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
Am Heart J
; 263: 73-84, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192697
3.
Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
Catheter Cardiovasc Interv
; 101(4): 687-700, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36807456
4.
Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.
Am Heart J
; 235: 140-148, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33609498
5.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Lancet
; 394(10205): 1243-1253, 2019 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31488372
6.
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Lancet
; 392(10149): 737-746, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30170848
7.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Lancet
; 384(9960): 2111-22, 2014 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189359
8.
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
Cardiovasc Revasc Med
; 34: 3-10, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33653633
9.
A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE).
EuroIntervention
; 18(2): e132-e139, 2022 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34794936
10.
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Int J Cardiol
; 334: 37-41, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887341
11.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
JACC Cardiovasc Interv
; 14(6): 639-648, 2021 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33727005
12.
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
J Am Heart Assoc
; 8(22): e013607, 2019 11 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31696762
13.
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
EuroIntervention
; 14(6): 692-699, 2018 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205157
14.
Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents.
Am J Cardiol
; 119(4): 501-507, 2017 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27923461
15.
Performance of the Orsiro Hybrid drug-eluting stent in high-risk subgroups.
Minerva Cardioangiol
; 64(1): 55-73, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26542119
16.
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
J Am Heart Assoc
; 5(3): e003255, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26979080
17.
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Circ Cardiovasc Interv
; 8(6)2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26043895
18.
Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial.
JACC Cardiovasc Interv
; 9(9): 981-3, 2016 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27151616
Resultados
1 -
18
de 18
1
Próxima >
>>